Deucravacitinib improved psoriasis compared with placebo and apremilast in a phase 3 study, Bristol Myers Squibb announced in a press release.
The global phase 3 POETYK PSO-1 and POETYK PSO-2 studies evaluated deucravacitinib 6 mg, an oral, selective tyrosine kinase 2 inhibitors, in patients with moderate to severe plaque psoriasis.
The first study enrolled 666 patients, while the second enrolled 1,020. Both multicenter, randomized, double-blind trials compared the drug, taken once daily, with placebo and 30 mg twice-daily Otezla (apremilast, Amgen).
After 16 weeks of treatment in the POETYK PSO-2 study, significantly more patients on deucravacitinib had at least a 75% improvement in Psoriasis Area and Severity Index and a static Physician’s Global Assessment score of clear or almost clear compared with those on placebo, the release said.
Those treated with deucravacitinib also showed superior improvement in PASI 75 and sPGA compared with those on apremilast.
“The encouraging data we have seen to date suggests deucravacitinib may become an important oral treatment option for people living with psoriasis. We look forward to discussing the results from the POETYK PSO-1 and POETYK PSO-2 registrational studies with health authorities, with the goal of offering this novel therapy to those suffering from this serious disease as soon as possible,” Samit Hirawat, MD, executive vice president and chief medical officer of global development at Bristol Myers Squibb, said in the release.
more recommended stories
Kaempferol: A Breakthrough in Allergy ManagementKaempferol, a dietary flavonoid found in.
Early Milk Cereal Drinks May Spur Infant Weight GainNew research published in Acta Paediatrica.
TaVNS: A Breakthrough for Chronic Insomnia TreatmentA recent study conducted by the.
First-of-Its-Kind Gene-Edited Pig Kidney: Towana’s New LifeSurgeons at NYU Langone Health have.
Just-in-Time Training Improves Success & Patient SafetyA study published in The BMJ.
ChatGPT Excels in Medical Summaries, Lacks Field-Specific RelevanceIn a recent study published in.
Study finds automated decision minimizes high-risk medicine combinations in ICU patientsA multicenter study coordinated by Amsterdam.
Study Discovers Connection Between Omicron Infection and Brain Structure Changes in MenA recent study in the JAMA.
Advancing COPD Prognosis: Deep Learning ModelsResearchers conducted a meta-analysis in a.
4 in 1 Test for Swine Flu, COVID-19, RSV, and InfluenzaIn the United Kingdom, the first.
Leave a Comment